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With the advent of whole organ decellularization, extracellular matrix scaffolds suitable for
organ engineering were generated from numerous tissues, including the heart, lung, liver,
kidney, and pancreas, for use as alternatives to traditional organ transplantation. Biomedical
researchers now face the challenge of adequately and efficiently recellularizing these organ
scaffolds. Herein, an overview of whole organ decellularization and a thorough review of
the current literature for whole organ recellularization are presented.The cell types, delivery
methods, and bioreactors employed for recellularization are discussed along with commer-
cial and clinical considerations, such as immunogenicity, biocompatibility, and Food and
Drug Administartion regulation.
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INTRODUCTION
An effective alternative to traditional organ transplantation is
needed in order to increase the number of organs available for
transplantation, decrease patient wait-list times, and improve
long-term outcomes. In an effort to address this need, research
focused on whole organ tissue engineering has flourished over the
last 5 years. Since the first reports of skin tissue engineering over
30 years ago, tremendous progress has been made in engineering
tissues such as skin, cartilage, or bladder (Hall et al., 1966; Spira
et al., 1969; Burke et al., 1981; O’Connor et al., 1981). However,
the engineering of whole organs has been impeded by the lack of
an adequate scaffold. Thus, the recent surge of research in whole
organ engineering can also be attributed to the implementation of
a technique known as decellularization to whole organs.
Decellularization removes cells from the extracellular matrix
(ECM) of a tissue to produce a three-dimensional organ scaf-
fold (Gilbert et al., 2006; Badylak et al., 2009, 2011; Crapo et al.,
2011). Decellularization of “simple” tissues and small organ biop-
sies was initially reported in the late 80s (Lwebuga-Mukasa et al.,
1986). Nearly two decades later, decellularization was successfully
adapted for the generation of a whole-heart scaffold (Ott et al.,
2008). In the subsequent years, intact lungs, livers, kidneys, and
pancreas from rodents, pigs, primates, and humans have been
decellularized using similar approaches (Ross et al., 2009; Ott
et al., 2010; Petersen et al., 2010; Price et al., 2010; Shupe et al.,
2010; Uygun et al., 2010; Baptista et al., 2011; Barakat et al., 2012;
Bonvillain et al., 2012; Orlando et al., 2012, 2013; Sullivan et al.,
2012; Goh et al., 2013; Mirmalek-Sani et al., 2013a; Song et al.,
2013). Prior to this development, creation of a full-scale scaffold
with the intricate architecture and composition needed to engineer
functional organs was very challenging.
Decellularized scaffolds have been seeded with various cell
types, which has resulted in reports of tissue-specific function-
ality in vitro as well as in vivo after short-term transplantation
into animal models (Ott et al., 2008, 2010; Petersen et al., 2010;
Uygun et al., 2010; Bao et al., 2011; Song et al., 2013; Jiang et al.,
2014; Kadota et al., 2014; Robertson et al., 2014). Despite remark-
able progress, significant challenges still exist, namely scaling up
techniques to human-sized organs, finding clinically relevant cell
types for recellularization, and completely rebuilding the vascu-
lature and parenchyma of organ scaffolds for long-term function
post-transplantation.
The aim of this review is to provide an overview of the recent
progress and emerging challenges in whole organ engineering.
DECELLULARIZATION FOR GENERATION OF ORGAN
SCAFFOLDS
DECELLULARIZED ORGAN MATRICES: WHAT’S LEFT BEHIND?
Defining decellularization
Decellularization employs detergents, salts, enzymes, and/or phys-
ical means to remove cells from tissues or organs while preserving
the ECM composition, architecture, bioactivity, and mechanics. A
plethora of decellularization methods exist for different applica-
tions [reviewed in (Gilbert et al. (2006), Badylak et al. (2011), and
Gilbert (2012)]. Because variation in decellularization methods
obscures data comparisons, determining an optimal decellulariza-
tion method is somewhat enigmatic. Nevertheless, with an ever
growing list of new publications, the feasibility of whole organ
decellularization is indisputable.
The key criteria for comparison of decellularization methods
are the efficiency of cell removal and the adequacy of ECM reten-
tion. Crapo et al. recommended that removal of cells be evaluated
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visually via DAPI or hematoxylin and eosin (H&E) staining cou-
pled with quantification and gel electrophoresis. The goal is to
have <50 ng dsDNA/mg tissue (dry weight) remaining after decel-
lularization; in addition, the fragment length of the DNA should
be <200 bp (Crapo et al., 2011). Adherence to these guidelines
should help reduce the immunogenicity of scaffolds and render
them suitable for clinical application.
The effect of decellularization on ECM composition
In regards to ECM retention after decellularization, evaluation of
the composition, structure, and mechanics of organ scaffolds is
critical. Maintenance of the architecture and composition of the
ECM is the greatest benefit of decellularized whole organ scaf-
folds; however, it is also one of the main challenges. Although
many groups have demonstrated retention of collagen, laminin,
elastin, and fibronectin after decellularization, reduction or deple-
tion of ECM proteins and growth factors has also been reported
(Akhyari et al., 2011; Petersen et al., 2012; Wallis et al., 2012; Ren
et al., 2013; Caralt et al., 2015). Petersen et al. (2012) reported
that lung decellularization methods differentially affect ECM pro-
teins; sodium dodecyl sulfate (SDS) depleted elastin and collagen
to a greater degree than decellularization using CHAPS deter-
gent, but both detergents substantially reduce glycosaminoglycan
content. Comparing four rat heart decellularization protocols,
Akhyari et al. (2011) concluded that none of the protocols were
ideal for generating intact scaffolds. They found that if a proto-
col led to better preservation of ECM proteins, it largely failed to
remove cell debris. Conversely, when cell debris was adequately
reduced, retention of ECM proteins suffered. Similar results have
been reported for optimization of kidney decellularization (Caralt
et al., 2015). Although kidneys decellularized using Triton X-100
retained growth factors and ECM components, cells were not ade-
quately removed; whereas, decellularization with SDS was able to
sufficiently remove cells while preserving the ECM (Nakayama
et al., 2010, 2011; Orlando et al., 2012; Sullivan et al., 2012; Caralt
et al., 2015). Therefore, striking a balance between cell removal and
ECM preservation is vital to deriving the optimal decellularization
protocol. It is important to note that the optimal procedure may
be different for each organ due to their unique anatomy.
The effect of decellularization on ECM structure
The retention of major ECM components, such as collagen and
laminin, lends to preservation of the ultrastructure of the scaf-
fold, which may facilitate recellularization by providing spatial
orientation. Corrosive casting has been used to demonstrate that
important parenchymal structures, such as the bile duct of rat liv-
ers and the bronchial tree and alveoli of rat lungs, are intact after
decellularization (Soto-Gutierrez et al., 2011; Kajbafzadeh et al.,
2014). For heart scaffolds, heterotopic implantation demonstrated
that the tricuspid valve was competent while scanning electron
microscopy (SEM) showed retention of myocardial and epicardial
fibers (Ott et al., 2008). SEM was also used to demonstrate that
the glomerular infrastructure of the kidney and the duct system
of the pancreas is intact after decellularization (Goh et al., 2013;
Orlando et al., 2013).
In addition to the parenchymal structures, the mainte-
nance of an intact microvasculature is critical for subsequent
recellularization of organ scaffolds. It has been shown by micro-
CT, perfusion of dyes or microbeads, angiography, and corrosion
casting that the structure of the vascular tree is intact after decellu-
larization of hearts, livers, kidneys, lungs, and pancreas (Ott et al.,
2008; Petersen et al., 2010; Uygun et al., 2010; Baptista et al., 2011;
Barakat et al., 2012; Orlando et al., 2012; Sullivan et al., 2012;
Goh et al., 2013; Mirmalek-Sani et al., 2013a; Scarritt et al., 2014;
Caralt et al., 2015). Preservation and subsequent reconstitution of
the microvasculature and capillary beds will be a crucial aspect to
successful recellularization.
In this regard, there have been conflicting reports that reflect
the variability of different decellularization techniques. Decel-
lularization of rat livers using 0.5 or 1% Triton X-100 pre-
served the hierarchical vascular structure; in contrast, 1% SDS
led to nearly complete collapse of the vascular network (Shi-
rakigawa et al., 2012). However, rat lungs decellularized using
SDS and Triton X-100 failed to maintain capillary integrity while
decellularization using sulfobetaine-10/16 amphoteric detergent
and Triton X-200 had significantly less extravasation from the
vasculature than perfusion-decellularized lungs (Nagao et al.,
2013).
In addition to the detergent used, the delivery method also
impacts the microvasculature. Constant pressure-based decellu-
larization, but not constant flow, maintained the vascular integrity
of rat lung scaffolds (Guyette et al., 2014). To this end, some
groups employ gravity-based or pressure-controlled decellular-
ization (Ross et al., 2009; Guyette et al., 2014; Scarritt et al.,
2014).
The effect of decellularization on scaffold mechanics
Scaffold mechanics are contingent upon ECM composition and
structure. Therefore, as an additional evaluation of ECM retention,
many researchers have employed the use of traditional engineer-
ing techniques such as atomic force microscopy (AFM) and uni-
or bi-axial mechanical testing to assess the biophysical properties
of organ scaffolds. In many cases, decellularization affects matrix
stiffness due to removal of cells and damage to ECM components.
After perfusion-decellularization of mouse pancreas, the Young’s
elastic modulus was three times greater than native pancreas,
indicating stiffening (Goh et al., 2013). In contrast, decellulariza-
tion of porcine kidney slices decreased stiffness (Nakayama et al.,
2010). For heart tissue engineering, bi-axial mechanical testing
revealed that the tangential modulus was increased longitudinally
and circumferentially after decellularization of rat ventricles (Ott
et al., 2008). Bi-axial testing of decellularized porcine hearts also
showed increased stiffness (Wang et al., 2010). In contrast, ball
burst testing of decellularized porcine ventricle indicated that the
maximum force, as well as the extension at maximum force, was
not statistically different than native hearts (Wainwright et al.,
2010). For lung tissue engineering, ventilation is dependent on
appropriate lung compliance and elastance. Thus, the mechanical
performance of lung scaffolds has been evaluated using pressure–
volume curves (Ott et al., 2010; Petersen et al., 2010; Price et al.,
2010). Although decellularized lung scaffolds displayed hysteresis,
they also displayed decreased compliance, which was attributed to
the removal of surfactant and the depletion of elastin (Daly et al.,
2011).
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Changes in scaffold stiffness can affect cell fate, particularly in
stem cells that can differentiate based on mechanotransduction
(Engler et al., 2006, 2007; Reilly and Engler, 2010; Pennesi et al.,
2011; Tse and Engler,2011). Mechanical conditions closest to phys-
iological values will likely direct or maintain the differentiation
state of cells. When evaluating stem cell differentiation, matrices
with an elastic modulus similar to brain (~1 kPa) were neurogenic
while matrices mimicking muscle (10 kPa) or bone (100 kPa) were
myogenic or osteogenic, respectively (Engler et al., 2006). Thus,
the outcome of organ recellularization can be influenced by the
mechanical environment sensed by seeded cells.
RECELLULARIZATION OF THE PARENCHYMA OF ORGAN
SCAFFOLDS
Since the pivotal publication by Ott et al. (2008) demonstrating
decellularization of a rat heart, whole organ bioengineering has
acquired the attention of scientists and lay-people alike with the
goal of creating patient-specific, transplantable organs. Deriva-
tion of scaffolds that retain an organ’s three-dimensional structure
and composition was the first step, but the task of effective recel-
lularization remains. Recellularization requires appropriate cell
sources, an optimal seeding method, and a physiologically rele-
vant culture method, undoubtedly to be accomplished using a
bioreactor. For complete organ regeneration, the parenchyma, vas-
culature, and support components must be reestablished prior
to implantation. Many groups have already begun to evaluate
techniques and have provided encouraging headway to develop-
ing optimal recellularization strategies. However, the technology
required for whole organ culture has limited widespread investi-
gation due to complexity, specialization, and in some cases cost.
Recellularization studies that encompass implantation in vivo
are limited. Regardless, high-throughput studies of cell seeding
have provided invaluable insight. Tables S1–S5 in Supplemen-
tary Material provide a comprehensive overview of the organ
recellularization literature covering scaffold source, decellulariza-
tion method, cell types used for seeding, seeding method, culture
method, additional cues, and recellularization outcomes.
CELL TYPES FOR PARENCHYMAL RECELLULARIZATION
Fetal and adult cells
As can be seen in Figure 1, many different cell types have been used
for organ recellularization. A common theme in the organ bioengi-
neering literature is the use of fetal cells derived from the organ of
interest. In general, when these cells are seeded into scaffolds, they
retain their phenotypic markers and often display functionality as
well as relevant spatial or compartmental orientation (see Tables
S1–S5 in Supplementary Material for more details). Indeed, rat
lung scaffolds seeded with neonatal or fetal rat lung cells par-
ticipated in gas exchange after implantation (Ott et al., 2010;
Petersen et al., 2010). Neonatal renal cells showed similar suc-
cess when seeded rat kidneys produce urine in vivo (Song et al.,
2013). Multiple groups have used fetal hepatic cells for liver recel-
lularization with promising outcomes including urea and albumin
production (Baptista et al., 2011; Zhou et al., 2011; Barakat et al.,
2012; Sabetkish et al., 2014; Wang et al., 2014). Fetal cells provide
proof-of-concept but, nevertheless, are not viable cell types for
clinically relevant organ engineering.
Primary adult cells have also been evaluated for recellular-
ization. For example, human renal cells have been utilized for
seeding porcine kidney scaffolds, and human alveolar epithelial
cells, human lung fibroblasts, and human small airway epithe-
lial cells have been evaluated for recellularization of human or
porcine lung scaffolds (Sullivan et al., 2012; Nichols et al., 2013;
O’Neill et al., 2013). Although patient-derived primary cells can
be obtained from an organ biopsy or a donor organ, primary
cells have restricted proliferative capacities and can be difficult to
expand for repopulation of a human-sized organ scaffold.
Hepatocytes, for example, are ideal for liver bioengineering,
but the availability of human hepatocytes is limited to discarded
cadaveric livers (Palakkan et al., 2013). To compound the prob-
lem, culture of primary hepatocytes leads to a deterioration in
function and stability (Walldorf et al., 2004). Regardless, pri-
mary hepatocytes have been evaluated for liver recellularization
with mostly positive outcomes, which suggests that organ scaf-
fold culture allows hepatocytes to persist and proliferate better
than traditional culture (Uygun et al., 2010; Bao et al., 2011; Bap-
tista et al., 2011; Soto-Gutierrez et al., 2011; Zhou et al., 2011;
Barakat et al., 2012; Shirakigawa et al., 2013; Yagi et al., 2013).
With primary rat hepatocytes, Uygun et al. (2010) noted over 95%
of cells engrafted, and <20% were apoptotic during initial cul-
ture. Multiple groups saw similar percentages of engraftment with
varying levels of proliferation and apoptosis (Baptista et al., 2011;
Soto-Gutierrez et al., 2011; Barakat et al., 2012; Yagi et al., 2013).
In addition, hepatocyte-seeded scaffolds have been transplanted
by various groups. Bao et al. (2011) transplanted recellularized
liver into rats with 90% hepatectomy and reported survival for
up to 72 h. After heterotopic transplantation, Uygun et al. (2010)
reported that perfusion with minimal ischemic damage to seeded
hepatocytes was observed for up to 8 h; in vitro albumin, urea, and
bile functions were reported as well.
Embryonic stem cells
Keeping in mind the ultimate goal of producing a patient-specific
organ, investigators have turned to stem or progenitor cells as
a source for recellularization. Stem and progenitor cells are of
interest because they are easily expanded in culture and able to dif-
ferentiate into multiple lineages. Of the papers reviewed in Tables
S1–S5 in Supplementary Material, embryonic and mesenchymal
stem cells (ESCs and MSCs, respectively) were the most prevalent
stem cell types used for recellularization. ESCs were often used to
assess the effect of organ matrices on differentiation. Decellular-
ized rat kidney scaffolds were seeded with mouse ESCs without
any exogenous pro-differentiation signals (Ross et al., 2009, 2012;
Bonandrini et al., 2014). Upon seeding, ESCs expressed renal
and endothelial markers while pluripotency decreased. On the
other hand, Nakayama et al. (2013) seeded human ESCs onto rhe-
sus macaque lung and kidney scaffold slices. Although the ESCs
expressed kidney and lung markers, expression was not specific
to the organ. Mouse ESC differentiation was also assessed on
lung scaffolds in comparison to Gelfoam, Matrigel, and collagen
I hydrogel matrix (Cortiella et al., 2010). Based on the expression
of lung markers, Cortiella et al. demonstrated that lung scaffolds
facilitated differentiation of ESCs into epithelial and endothelial
lineages.
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FIGURE 1 | Cell types used for organ scaffold recellularization. The cells
listed above have been reportedly used for recellularization of the specified
organ. Abbreviations: embryonic stem cells (ESCs); bone marrow-derived
stem cells (BMSCs); adipose-derived stem cells (ASCs); mesenchymal stem
cells (MSCs); induced pluripotent stem cells (iPSCs); human umbilical vein
endothelial cells (HUVECs); small airway epithelial cells (SAECs); pulmonary
alveolar epithelial cells (PAECs); microvascular endothelial cells (MVECs);
alveolar epithelial type II cells (AETII).
Organ ECM is likely limited in its ability to provide all of
the necessary signals required for differentiation of ESCs. This
limitation may explain why Nakayama et al. did not observe
an organ-specific effect of kidney versus lung scaffolds on ESC
differentiation. This idea led Ng et al. (2011) to theorize that
pre-differentiation of ESC could enhance organ-specific differ-
entiation. Human ESCs were compared to ESCs differentiated
into mesendodermal cells (MECs) for recellularization of mouse
heart scaffolds. Both cell types lost expression of stem mark-
ers and gained expression of cardiac markers, but only ESCs
expressed myosin heavy chain 6 while only MECs expressed
myosin light chain 2 and 7. After subcutaneous implantation
in immunodeficient mice for up to 6 weeks, MEC-seeded scaf-
folds contained more cells and were better vascularized than
ESC-seeded scaffolds. Although the role of organ scaffolds in ESC
differentiation is still unclear, scaffolds are likely better suited for
enhancing ESC differentiation, when coupled with the appropriate
differentiation cocktails, rather than differentiation media alone.
Mesenchymal stem cells
Mesenchymal stem cells hold great promise for organ engineer-
ing due to their clinical applicability (Gimble et al., 2012). MSCs
can be isolated from a patient, from sources such as bone marrow
or adipose tissue, and expanded in culture to physiologically rel-
evant numbers. In addition to their ability to differentiate into
various cell types, MSCs are involved in tissue repair and can
provide stromal support through the secretion of cytokines and
chemokines, a role that is likely to facilitate better integration of
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seeded organs upon transplantation (Toma et al., 2002; Wang et al.,
2005; Qian et al., 2008). Interestingly, there is evidence that organ
scaffolds enhance the differentiation of MSCs (Jiang et al., 2014).
Jiang et al. statically cultured mouse bone marrow-derived MSCs
on mouse liver scaffolds in the presence of hepatic differentiation
media for 4 weeks. The three-dimensional liver scaffold signifi-
cantly enhanced MSC differentiation into hepatocytes in compar-
ison to traditional 2D cell culture. In addition, seeded liver scaffold
sections rescued liver function after transplantation into a mouse
model of fulminant hepatic failure. Ji et al. (2012) took a slightly
different approach by harvesting MSC-derived hepatocytes from
liver scaffolds and implanting them into mice with CCl4-induced
fibrotic livers. The cells were able to increase survival, improve
liver function, and decrease collagen deposition to restore liver
architecture. Heart scaffolds were also able to enhance MSC dif-
ferentiation into cardiomyocytes, particularly when coupled with
mechanical and electrical stimulation (Wang et al., 2013).
The ability of the scaffold to promote MSC differentiation is
likely due to organ-specific cell–ECM communications (Guilak
et al., 2009; Zhang et al., 2009; Reilly and Engler, 2010). Shamis
et al. (2011) determined that the organized, organ-specific stroma
of lung or liver matrices was required for localized cell differen-
tiation of hepatocytes and alveolar cells. Both human adipose-
and bone marrow-derived MSCs (ASCs and BMSCs, respectively)
differentiated toward pulmonary epithelial lineages when seeded
into decellularized rat lungs (Mendez et al., 2014). Mendez and
colleagues reported that both ASCs and BMSCs expressed pro-
surfactant protein C (alveolar type II cell marker), but only ASCs
expressed Clara cell secretory protein (club cell marker), and
the BMSCs expressed cytokeratin-5 (basal epithelial cell marker).
ASCs also showed a propensity for attaching in the upper air-
ways of lung scaffolds, an ability that was not demonstrated by
BMSCs, which suggests that these two types of MSCs may have
unique attachment properties. Several other groups have seeded
lung scaffolds with MSCs and demonstrated attachment and per-
sistence in culture (Daly et al., 2011; Nichols et al., 2013; O’Neill
et al., 2013). Indeed, MSCs have been shown to attach to lung scaf-
folds regardless of decellularization method, sterilization method,
storage time, or disease state suggesting that MSCs have a wide-
range of application in recellularization (Booth et al., 2012; Wallis
et al., 2012; Bonenfant et al., 2013; Sokocevic et al., 2013; Scarritt
et al., 2014; Wagner et al., 2014).
Stem cells from amniotic fluid, cord blood, placenta, amnion,
olfactory mucosa, and Wharton’s jelly may also have application
in organ engineering. For example, umbilical cord blood-derived
progenitor cells differentiated into respiratory epithelial cells
(Berger et al., 2006). Recently, human amniotic fluid derived stem
cells were seeded onto porcine pancreas scaffolds and attached,
migrated, and expanded throughout the scaffold (Mirmalek-Sani
et al., 2013a). Oberwallner et al. (2014) evaluated human umbilical
cord blood MSCs for seeding sections of human heart scaffolds.
These MSCs infiltrated the matrix and displayed increased viabil-
ity and metabolism when grown in the presence of the scaffold.
Thus, these alternative sources of stem cells may also be of value
to organ recellularization.
Organ-specific stem cells, although not yet applied to organ
engineering, would provide a physiologically relevant cell source
for recellularization. For example, lung-resident MSCs have been
identified in mice and humans that have the ability to differentiate
into club cells and alveolar type I and type II cells (Lama et al.,
2007; Hoffman et al., 2011; Wagner et al., 2013).
Induced pluripotent stem cells
Another promising cell type for organ recellularization is induced
pluripotent stem cells (iPSCs). iPSCs are generated by reprogram-
ing somatic cells using specific pluripotent genes that render an
“embryonic-like” state (Yu et al., 2007). This approach could facil-
itate the use of patient-derived cells to provide a cell source for the
construction of patient-specific organs. Recent investigations have
harnessed iPSCs for lung recellularization (Ghaedi et al., 2013).
Human iPSCs were differentiated to alveolar epithelial type II
cells (AETII) with high efficiency. Cells with an AETII phenotype
expressed typical lung markers including surfactant protein C and
B. When these cells were seeded into rat and human lung matrices,
they readily adhered, proliferated, and maintained expression of
alveolar markers. Additionally, AETII cells could be induced to dif-
ferentiate into an AETI phenotype. For recellularization of mouse
heart matrices, iPSC-derived myocyte progenitors were delivered
to the scaffold via the aorta (Lu et al., 2013). The cells repopu-
lated the matrix and began spontaneous contraction after 20 days;
however, echocardiogram revealed an irregular wave morphology
suggesting that the cells lacked an organized conduction system.
Regardless, the endocardium harbored muscle-like and vessel-like
structures formed by seeded iPSC-myocytes. The resulting tissue
was shown to be drug responsive to an adrenergic agonist as well
as an inducer of ventricular arrhythmias. Conversely, Oberwallner
et al. (2014) compared heart recellularization with iPSC-derived
cardiomyocytes to MSCs and found that iPSC-cardiomyocytes
attached less fervently than MSCs even if fibronectin was added
to scaffolds to enhance adhesion. Thus, the use of iPSCs for organ
recellularization requires additional investigation.
Support cells
The integration of mural, stromal, immune, and interstitial cell
types is also of utmost importance to complete recellularization in
order to generate an organ that can renew and respond to injury.
Fibroblasts, for example, may have a significant role in matrix
remodeling in organ scaffolds. In addition, fibroblasts have been
shown to enhance AETII cell function (Adamson, 1992; Griffin
et al., 1993). Immune cells such as Kupffer cells for the liver or
alveolar macrophages may enhance recellularization. Pericytes and
nerve cells may also be important contributors to complete recel-
lularization. A report by Barakat et al. (2012) used human fetal
stellate cells, pericytes that surround the sinusoids of the liver, to
enhance the attachment and viability of human fetal hepatocytes
seeded into porcine liver scaffold segments. To enhance hepato-
cyte recellularization of rat liver scaffolds, Kadota et al. (2014)
co-seeded BMSCs as a supportive cell type. The inclusion of the
BMSCs enhanced hepatocyte integration into the scaffold by facil-
itating migration into the parenchymal space where hepatocytes
aligned in cords. The BMSCs were principally located in the portal
area and intraluminal surface of vessels suggesting a different niche
or binding affinity than the hepatocytes. Not only does this demon-
strate the value of incorporating support cells into recellularization
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strategies but also the need for multiple cell types for complete
coverage of organ scaffolds.
PARENCHYMAL RECELLULARIZATION: WHOLE ORGAN SEEDING
METHODS
Although some of the same cell types have been evaluated for
recellularization of different organs, the seeding method is highly
dependent on the organ itself. A vascular tree is common to
all organs, but additional non-vascular routes can be of use for
seeding. The delivery method is also of import to cell seed-
ing due to the mechanical influence of fluid shear stress and
pressure. Seeding methods for each organ are presented. Tables
S1–S5 in Supplementary Material include publications describing
the technical details of seeding methods for each organ. These
investigations provide critical clues toward generating optimal
seeding strategies.
Liver
The liver can be seeded from multiple vascular routes, namely
the portal vein, the hepatic artery, or the inferior vena cava (IVC)
(hepatic veins). Most groups use either the portal vein or the vena
cava (Wang et al., 2014); however, employing the use of multiple
routes very likely facilitates the spatial arrangement of cells. Indeed,
perfusion seeding of liver scaffolds via the vena cava deposited cells
in the pericentral area, while seeding via the portal vein deposited
cells in the periportal area (Baptista et al., 2011). Interestingly,
Baptista et al. also noted that the directionality of flow during
perfusion affected the alignment of cells.
Another group found that seeding via the portal vein or hepatic
vein was not as effective as seeding hepatocytes, suspended in
collagen gel, directly into the liver using a needle (Shirakigawa
et al., 2013). Direct injection of cells, however, may lead to cell
aggregation, poor cell engraftment, and insufficient distribution
throughout the scaffold. A study by Soto-Gutierrez et al. (2011)
demonstrated this by evaluation of different methods to recellular-
ize the liver parenchyma of rat scaffolds with mouse hepatocytes.
Five injections into the hepatic lobes using a needle generated
<13% engraftment of seeded cells. Perfusion seeding, on the other
hand, led to more favorable outcomes. Cells introduced to the liver
by continuous media perfusion within a bioreactor resulted in
roughly 70% cell engraftment, while approximately 86% engraft-
ment was achieved when infusing cells directly into the liver
perfusion circuit in 10–15 min steps. This “step-wise” method was
also successfully employed (with >95% engraftment) by Uygun
et al. (2010) when seeding primary rat hepatocytes into rat liver
scaffolds, by Yagi et al. (2013) when seeding primary porcine hepa-
tocytes into porcine liver scaffolds, and by Jiang et al. (2014) when
seeding mouse BMSCs into mouse scaffolds. Multiple infusions
will likely be necessary to deliver an adequate number of cells to
reconstitute the liver sufficiently. Indeed, multi-step serial infu-
sion was used to increase the number of seeded cells from 50 to
200 million (representing 20% of a rat’s liver mass) (Uygun et al.,
2010). To account for 5–10% of the liver mass of a human lung,
10 billion hepatocytes would be required (Caralt et al., 2014).
Overall, perfusion seeding is most efficient at distributing cells
throughout the liver scaffold, and future investigations would
likely benefit from utilizing multiple seeding routes. In addition,
the use of the hepatic duct system for seeding has not yet been
investigated.
Kidney
The kidney can be seeded via the vasculature or the ureter; how-
ever, antegrade perfusion through the renal artery is the most
common route in the kidney recellularization literature. Bonan-
drini et al. (2014) seeded mouse ESCs at 0.2 mL/min through the
renal artery and reported an even distribution of cells with over
97% cell attachment. Caralt et al. (2015) reported that renal arte-
rial perfusion seeding of 40 million human renal cortical tubular
epithelial (RCTE) cells at 25 mL/min led to about 50% coverage
of the renal area.
Two groups utilized the ureter for seeding (Ross et al., 2009;
Song et al., 2013). In static culture experiments, Ross and col-
leagues saw better distribution and retention of cells when seeding
through the renal artery than through the ureter (>95% retained
versus ~50% retained). However, Song et al. (2013) noted site-
specific adhesion of neonatal rat kidney cells as well as polarity
when seeding through the ureter. Kidney scaffolds seeded with
neonatal kidney cells and human umbilical vein endothelial cells
(HUVECs) could produce urine in vitro and in vivo.
Song et al. enhanced seeding through the ureter by generating a
pressure gradient via a vacuum. This may account for the discrep-
ancy in the observations of ureter-based seeding reported by Ross
et al. in comparison to Song et al. Another important observation
of Song et al. was that a vacuum pressure exceeding 70 cm H2O
damaged the parenchymal tissue while a pressure of 40 cm H2O
was acceptable. This illustrates the importance of the mechanical
environment during seeding.
Lung
The lung has two seeding routes, the vasculature and the air-
way. Utilizing the trachea for seeding of fetal rat lung cells and
the pulmonary artery for seeding of HUVECs, Ott et al. (2010)
demonstrated reconstitution of the alveolar-capillary membrane
lending to gas exchange in vitro and in vivo. Both cell types were
seeded by gravity and then cultured in a bioreactor at a set pressure
range of 10–15 mmHg. Petersen et al. seeded cells via both routes
as well; however, cells were instilled at 3 mL/min into the vascula-
ture or as a bolus into the airway until the lungs were fully inflated
(Petersen et al., 2010; Calle et al., 2011). This group also demon-
strated gas exchange after implantation of regenerated lungs. Price
et al. (2010) on the other hand, seeded cells via the trachea only
and utilized ventilation-based organ culture at 180 breaths/min.
Trachea-only seeding was also employed by Cortiella et al. (2010)
who used a rotating bioreactor for organ culture. After these four
initial reports, many other groups adopted similar seeding meth-
ods (coupled with static culture) to evaluate different cell types
for recellularization (see Table S3 in Supplementary Material for
more information).
Ultimately, complete lung recellularization will likely be accom-
plished by seeding the airway and the vasculature, via both the
pulmonary artery and pulmonary veins. The main challenge will
be distributing cells throughout the branching structure of the
airway and vasculature for full-coverage of the proximal and distal
regions of the scaffold.
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Heart
For heart recellularization, cells can be seeded into the coronary
arteries via the aorta. iPSCs delivered via the aorta were able to
repopulate a mouse heart matrix (Lu et al., 2013). Because con-
tinuous perfusion culture washed out most of the cells, Lu et al.
opted to perfuse the heart at 8-h intervals. By the end of the culture
period, iPSC-derived cardiomyocytes formed myofilaments, were
drug responsive, and spontaneously contracted. Ng et al. (2011)
seeded a single bolus of MECs or ESCs into the aorta of mouse
heart scaffolds followed by static culture for 2 weeks. Though no
beating was observed after subcutaneous implantation, seeded
scaffolds were vascularized by the host and cells expressed cardiac
and endothelial markers.
Aorta-based seeding of the coronary arteries has promise, but
seeding the ventricular wall, on the other hand, is more difficult.
Cell engraftment into the ventricular wall was accomplished by
direct injection with a needle by multiple groups (Ott et al., 2008;
Crawford et al., 2012; Hulsmann et al., 2013; Robertson et al.,
2014; Weymann et al., 2014). Ott et al. (2008) conducted five serial
injections of neonatal rat cardiac cells into the anterior left ventri-
cle; this was followed by bioreactor culture with 20 mL/min atrial
flow and 6 mL/min coronary flow as well as electrical stimulation.
Although, dense cellularity was noted at the injection site, cells
were not well distributed throughout the scaffold. Weymann et al.
(2014) also seeded cells using five injections in the left ventricle
of porcine heart scaffolds and reported approximately 50% cellu-
larity at the injection site, but less seeding in the distal portions.
Regardless, Weymann et al. observed electrical activity, and Ott
et al. (2008) noted the formation of contractile fibers, cardiomy-
ocyte contraction in response to electrical stimuli, pump function,
and drug responsiveness.
Pancreas
Because pancreas decellularization is less widely studied than other
organs, investigation of recellularization is currently limited. The
pancreas can be seeded through the pancreatic duct or the vascu-
lature. The vasculature can be accessed via the portal vein, splenic
artery, superior mesenteric artery and veins, or superior pancre-
aticoduodenal artery. Multiple cell infusions via various routes
have been efficacious for pancreas recellularization. Goh et al.
(2013) seeded MIN-6 pancreatic beta cells into the portal vein
and AR42J pancreatic acinar cells via the pancreatic duct by three
1 mL perfusion steps (with a 20 minute static incubation between
steps). MIN-6 cells attached in luminal spaces and larger blood
vessels while AR42J cells lined the tubular ductal spaces; no co-
localization of the two cell types was observed suggesting that
dual seeding is beneficial for complete pancreas recellularization.
OPTIMIZATION OF PARENCHYMAL SEEDING
Coating of organ matrices has been employed as a technique to
enhance cell seeding. After Lecht et al. (2014) determined that
the integrin-binding profile of mouse ESCs allows adhesion to
laminin and fibronectin but not collagen I or IV, they coated rat
lung scaffolds with laminin and fibronectin to enhance seeding.
Coating was accomplished by instilling lung scaffolds with condi-
tioned media from A549 pulmonary epithelial cells. They observed
enhanced binding of mouse ESCs, a 2.3-fold increase in cellular-
ity, and better cell dispersion throughout the scaffold (Lecht et al.,
2014). Another group evaluated coating mouse lung scaffolds with
Matrigel or collagen I (Jensen et al., 2012). Mouse ESCs seeded
into Matrigel-coated or uncoated scaffolds expressed lung mark-
ers (pro-SPC and TTF-1) similarly (Jensen et al., 2012). However,
mouse ESCs seeded into collagen I-coated matrices exhibited no
pro-SPC expression and minimal TTF-1 expression. Thus, coat-
ing with collagen I was actually detrimental to the differentiation
of mouse ESCs and coating with Matrigel did not enhance dif-
ferentiation, which may support the findings of Lecht et al. who
reported that mouse ESCs do not adhere to collagen I. The lack of
lung-specific differentiation may also be due to increased stiffness
caused by collagen coating. Indeed, Jensen et al. reported that col-
lagen coating changed the mechanical properties of the matrix; as
previously discussed, stem cells can differentiate according to the
stiffness of a matrix (Engler et al., 2006, 2007; Pennesi et al., 2011).
In addition to ESCs, multiple groups have investigated the
ECM binding preferences of MSCs and have shown that different
integrin-binding profiles affect stem cell attachment and differen-
tiation (Daly et al., 2011; Bonvillain et al., 2012; Frith et al., 2012).
Thus, it would be valuable to investigate the use of an ECM coating
technique to enhance MSC seeding of organ scaffolds.
Optimal cell density and cell number will need to be determined
for seeding. Increasing the cell density increases the possibility of
the formation of cell aggregates that could occlude vessels and
cause necrosis by impeding nutrient transfer. The use of EDTA
to prevent clusters has been suggested; however, the use of a cell
strainer can also reduce cell aggregates prior to seeding (Calle et al.,
2011). Excessively high cell numbers may also lead to vessel occlu-
sion. Thus, using low cell concentrations or multiple cell infusions
rather than a large, concentrated bolus of cells may be benefi-
cial. Indeed, multi-step cell infusions enhanced recellularization
of livers (Uygun et al., 2010; Soto-Gutierrez et al., 2011).
For the seeding of multiple cell types, many variables come into
play. Multiple cells can be seeded sequentially in the same route or
simultaneously in the same cell suspension. Indeed, Kadota et al.
(2014) found that simultaneous seeding of hepatocytes and MSCs
was superior to sequential seeding.
RECELLULARIZATION OF THE VASCULATURE OF ORGAN
SCAFFOLDS
The clinical success of any tissue-engineered construct is depen-
dent on its survival and integration into the body, particularly by
establishing a connection to the blood supply. Because the diffu-
sion limit of oxygen in the human body is 150–200µm, engineered
organs require a vascular network (Folkman and Hochberg, 1973).
In addition, the denuded vasculature of organ scaffolds is highly
thrombogenic even with anti-coagulation (Baptista et al., 2011;
Orlando et al., 2012; Robertson et al., 2014). Therefore, the vascu-
lature of an organ scaffold must be completely recellularized for
successful transplantation.
CELL TYPES FOR VASCULAR RECELLULARIZATION
Endothelial cells
Endothelial cells are the primary cell types used for vascular
recellularization. In the first report of organ decellularization
www.frontiersin.org March 2015 | Volume 3 | Article 43 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scarritt et al. Cellularization of whole organs
and recellularization, rat aortic endothelial cells were used. These
cells lined the coronary vessels of rat heart scaffolds lending to
decreased thrombogenicity upon implantation (Ott et al., 2008;
Robertson et al., 2014). For the re-endothelialization of rat lung
scaffolds, Ott et al. (2010) seeded ~66 million HUVECs by grav-
ity perfusion into the pulmonary artery and the pulmonary vein.
Engraftment from the pulmonary artery through the vascular
tree to the capillaries was observed after 5 days in a perfusion
bioreactor culture. Scaffolds that had been seeded with rat fetal
lung cells as well as HUVECs were implanted orthotopically
into rats for up to 14 days without any bleeding into the air-
ways, although edema was noted (Song et al., 2011). HUVECs
were also employed for re-endothelialization of rat kidney scaf-
folds and were able to line blood vessels throughout the scaffold
(Song et al., 2013). Scaffolds seeded with neonatal rat kidney cells
and HUVECs were able to be orthotopically implanted without
thrombi formation or hemorrhaging. HUVECs have also been
used for liver re-endothelialization by seeding through the portal
vein with cells seen lining large and small vessels (Baptista et al.,
2011; Shirakigawa et al., 2012, 2013).
Microvascular endothelial cells have the potential for vascular
recellularization. Cardiac microvascular endothelial cells perfused
into the portal vein of rat liver scaffolds lined the vasculature
and remained viable throughout bioreactor culture (Uygun et al.,
2010). Petersen et al. (2010) seeded lung microvascular endothelial
cells into rat lung scaffolds through the pulmonary artery using a
perfusion pump (at 3 mL/min). Transmission electron microscopy
identified tight junctions between some of the endothelial cells;
however, when scaffolds were implanted, thrombi and bleeding
into the airways were observed suggesting that revascularization
was incomplete.
Circulating endothelial colony forming cells could potentially
be isolated from a patient’s blood for clinically relevant re-
endothelialization of organ scaffolds. Indeed, endothelial colony
forming cells and blood outgrowth endothelial cells adhered and
dispersed throughout the vascular compartment of lung and heart
scaffolds (Crawford et al., 2012; Wagner et al., 2014).
Embryonic stem cell
In addition to recellularization of the parenchyma, stem cells
have also been considered for vascular recellularization. Mouse
ESCs seeded into the artery of decellularized rat kidneys and cul-
tured without any exogenous growth factors displayed a flattened
endothelial-like morphology within vascular structures (Ross
et al., 2009). In addition, these cells were positive for endothelial-
specific lectin and vascular endothelial growth factor receptor
(VEGFR) (Ross et al., 2012). Bonandrini et al. (2014) also seeded
murine ESCs into the renal artery of rat kidney scaffolds and
observed repopulation of the glomerular and peritubular capil-
laries. These cells expressed Tie-2 and CD31 endothelial markers
as early as 24 h after seeding, and CD31 expression increased
after 72 h.
Mesenchymal stem cells
Adipose-derived stem cells were able to attach to the vascular
matrix in lung scaffolds derived from healthy and hypertensive
rats; the cells lined the vasculature and persisted in static culture for
2 weeks (Scarritt et al., 2014). Although Scarritt et al. did not assess
endothelial differentiation, MSCs have been shown to differenti-
ate toward endothelial lineages based solely on their interaction
with endothelial ECM (Lozito et al., 2009a,b). In addition, both
ASCs and BMSCs have the ability to differentiate into smooth
muscle cells, which are a cell type that has not yet been assessed
for organ revascularization (Liu et al., 2007; Gong and Niklason,
2011; Marra et al., 2011). The role of smooth muscle in regulating
blood pressure and, hence, proper nutrient delivery throughout
the body lends to the importance of evaluating this cell type for
organ revascularization.
Induced pluripotent stem cells
Rat kidney scaffolds were re-endothelialized using human
endothelial cells derived from iPSCs (Caralt et al., 2015). The
iPSC-endothelial cells lined the branching structures of the vas-
culature and were found adjacent to the glomeruli. Lu et al.
(2013) used a similar approach for recellularization of mouse
heart scaffolds by differentiating human iPSCs and human ESCs
into multipotent cardiovascular progenitor cells. These cardio-
vascular progenitor cells were seeded into the matrix via the aorta
and then subsequently differentiated into cardiomyocytes, smooth
muscle cells, and endothelial cells by perfusion of growth factors.
Vessel-like structures were observed in the seeded scaffolds with
endothelial cells lining the endocardial surface as well as small
coronary arteries. Thus, iPSCs have shown promise for vascular
recellularization.
Support cells
Another approach that may be of interest for vascular recellulariza-
tion is the use of the stromal vascular fraction (SVF) from adipose
tissue. SVF is a heterogeneous cell mixture containing endothelial
cells, mural cells, and immune cells (Gimble et al., 2011; Bourin
et al., 2013). The use of a mixed cell population such as the SVF may
provide a better environment for engineering competent, renew-
able vasculature. Indeed, Nunes et al. (2013) generated a functional
liver mimic by suspending SVF cells and HepG2 human liver cells
within a collagen type I gel. After implantation into mice, the
SVF cells assembled into a functional vascular network that could
supply the HepG2 cells. Interestingly, SVF cells were often seen
in a perivascular location along the newly formed vasculature. In
addition, host-derived blood vessels that infiltrated the implanted
construct contained SVF cells.
The importance of mural cells to vascular tissue engineering has
been demonstrated in simple tissue constructs (Levenberg et al.,
2005; Rochon et al., 2010). These cell types may also be benefi-
cial for organ scaffold revascularization. Therefore, future studies
should incorporate mural cells such as pericytes and smooth
muscle cells to support the endothelium.
VASCULAR RECELLULARIZATION: SEEDING METHODS
Seeding of the vascular compartment is commonly accomplished
by perfusion through the vascular tree. Most groups employ a
perfusion pump, but some use gravity-driven apparatuses for vas-
cular seeding (Ott et al., 2010). Perfusion pressure and flow rate
will likely be the most influential parameters for vascular seeding
(Lichtenberg et al., 2006).
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Although many groups have seeded parenchymal cells via the
vasculature, investigation and optimization of revascularization
have been limited. A few groups have employed continuous perfu-
sion seeding at relatively low flow rates for seeding endothelial cells.
For recellularization of rat kidney scaffolds, HUVECs were per-
fused into the renal artery at 1 mL/min followed by an overnight
static incubation (Song et al., 2013). Cells lined the blood vessels
throughout the scaffold preventing leakage upon transplantation.
HUVECs seeded into the portal vein at 0.5 mL/min formed a
monolayer and decreased leaks upon blood perfusion (Shiraki-
gawa et al., 2012, 2013). Endothelial cells seeded at 3 mL/min
into the pulmonary artery dispersed throughout the matrix; how-
ever, bleeding into the airways was observed after orthotopic
transplantation (Petersen et al., 2010).
To date, most reports seed via a single route; however, seeding
the vasculature antegrade and retrograde may benefit complete
revascularization. Indeed, gravity-based seeding of HUVECs into
the pulmonary artery and pulmonary veins of rat lung scaffolds
prevented hemorrhaging and thrombosis after implantation (Ott
et al., 2010; Song et al., 2011). Therefore, seeding via the pulmonary
artery and veins by Ott et al. was likely better able to cover the
entirety of the vascular tree of lung scaffolds than arterial seeding
alone used by Petersen et al.
For the re-endothelialization of rat heart scaffolds, three dif-
ferent seeding routes (or combinations of routes) were evaluated
(Robertson et al., 2014). Rat aortic endothelial cells were infused
into the aorta, the brachiocephalic artery (BA), the inferior vena
cava (IVC), or both the BA and the IVC. The dual seeding method
resulted in the highest cellularity and a uniform distribution of
cells. Seeding via the BA delivered cells mostly to the vasculature of
the left ventricle while seeding via the IVC cellularized the vascula-
ture of the right ventricle. When perfused with human thrombin
and protein C, seeded endothelial cells exhibited thrombomod-
ulin and thrombin-mediated protein C activity. Heart scaffolds
that were re-endothelialized (in combination with seeding of rat
neonatal cardiac cells) and implanted heterotopically into rats for
7 days had less clotting than controls, illustrating the importance
of revascularization for organ engineering.
Baptista et al. (2011) compared antegrade seeding through the
portal vein and retrograde seeding through the vena cava of ferret
liver scaffolds. Seeding through the vena cava deposited endothe-
lial cells into the pericentral area while seeding via the portal vein
deposited cells in the periportal area. To evaluate dual seeding
using both routes, DAPI-staining cells were seeded into the portal
vein, and red fluorescent beads were instilled into the vena cava.
Baptista and colleagues observed the beads in the center of the
liver lobule surrounded by cells in the periportal area. Thus, for
liver recellularization, seeding via multiple routes led to better cell
distribution and coverage.
Because the vasculature is crucial to the successful integration
and survival of an organ transplant, complete revascularization
should be of utmost importance moving forward.
EVALUATION AND ENHANCEMENT OF VASCULAR RECELLULARIZATION
Transplantation of a regenerated organ with anastomosis to the
host blood supply is the ultimate assessment of successful re-
endothelialization; however, whole organ implantation studies
require technical experience with microsurgery for rodent models
and are costly for larger animal models. As a surrogate to transplan-
tation, blood perfusion has been used to evaluate revasculariza-
tion. Baptista et al. (2011) perfused blood through mouse endothe-
lial cell-seeded ferret liver scaffolds to assess platelet deposition.
Re-endothelialized scaffolds displayed significantly less platelet
aggregation than unseeded controls. Shirakigawa et al. (2013) per-
fused heparinized rat blood through HUVEC-seeded liver matri-
ces and reported that, in comparison to acellular matrices, there
were not as many leaks. Blood perfusion is a viable preliminary (or
pre-implantation) approach to assessing endothelialization, par-
ticularly because having an intact vascular barrier is critical to the
success of organ transplantation. As illustrated by Robertson et al.
(2014), perfusion with human thrombin and protein C is another
valuable approach to evaluating thrombomodulin and thrombin-
mediated protein C activity of re-endothelialized scaffolds prior
to implantation studies.
Because effective re-endothelialization would prevent throm-
bosis, an interesting approach to enhancing vascular recellular-
ization is “heparin layering” – a technique developed to render
scaffolds thromboresistant (Bao et al., 2011). The vascular com-
partment of rat liver scaffolds was coated with nine layers of
heparin using a layer-by-layer self-assembly technique. This tech-
nique rendered the scaffold thromboresistant for 3 h of implanta-
tion without endothelial cells. However, the application of heparin
layering alongside cell seeding is unknown.
Vascularization of organ scaffolds has made considerable
progress, but the generation of a competent vasculature for
long-term implantation has not yet been demonstrated.
BIOREACTORS FOR WHOLE ORGAN ENGINEERING
BIOREACTOR PARAMETERS AND APPLICATION
For the culture of regenerating organs, a bioreactor is required to
deliver nutrients to the core of the tissue via perfusion. This can be
accomplished with a very simple apparatus consisting of a perfu-
sion pump and an organ chamber with at least one inlet and one
outlet (Bao et al., 2011; Jiang et al., 2014; Sabetkish et al., 2014). On
the other hand, more sophisticated equipment has been developed
to monitor flow rate, pressure, oxygenation, and other parameters.
There are also bioreactors that can not only monitor these condi-
tions but can also manipulate them. For example,“self-correcting”
bioreactors that can adjust flow rate based on a max pressure or
that can infuse media based on glucose and lactate concentrations
have been described (Ott et al., 2008, 2010; Barakat et al., 2012;
Ross et al., 2012; Hulsmann et al., 2013).
In addition to perfusion, organ-specific stimuli are also cru-
cial to developing functioning organs. Mechanical cues may help
maintain phenotypes or promote differentiation of progenitor
cells (Clause et al., 2010; Ismail et al., 2012; Schmitt et al., 2012;
Zheng et al., 2012). Bioreactors should generate an environment
that is organ-specific and able to mimic in vivo conditions.
Liver
For liver engineering, the bioreactors described in recent publi-
cations commonly employ vascular perfusion without any other
mechanical influences. For example, multiple groups employ a
simple apparatus consisting of a peristaltic pump, an oxygenator,
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a bubble trap, and a chamber (without rigid surfaces) for rat
and pig liver culture (Uygun et al., 2010; Soto-Gutierrez et al.,
2011; Yagi et al., 2013; Kadota et al., 2014). For ferret liver culture,
Barakat et al. (2012) also used a perfusion-based system consist-
ing of a housing chamber with a sterile, vented organ cassette
modified from a LifePort Kidney Transporter. Using an infusion
pump, media was circulated between the cassette and a 3 L reser-
voir through oxygenator tubing connected to a mixture of air
and CO2.
For the regeneration of liver (and pancreas), perfusion through
the ductal system may be beneficial and has not yet been investi-
gated. In addition, a dual perfusion system for the portal vein and
the hepatic artery of the liver may also be beneficial.
Kidney
For recellularization of rat kidney scaffolds, Caralt et al. (2015)
constructed a perfusion-based system from two adjacent glass
flanges with a valve and septum. Kidney scaffolds were seeded
in the bioreactor at a high flow rate of 25 mL/min (232 mmHg) by
antegrade pulsatile perfusion to the renal artery before decreasing
the flow rate to 4 mL/min for culture. Although human RCTE cells
were able to seed approximately half of the renal area and form
tubular structures, Caralt et al. noted that oxygen access may have
been limited in some areas of the scaffold suggesting that further
optimization of bioreactor culture is needed.
Bioreactors that facilitate perfusion through both the renal
artery and the ureter may assist kidney regeneration. Song et al.
(2013) created a system for access to the renal artery as well as
the ureter. Their seeding chamber included a port for the with-
drawal of air to generate a negative pressure environment and
create a transrenal pressure gradient to facilitate seeding through
the ureter; however, for subsequent whole organ culture, perfusion
alone was utilized while the ureter drained passively into the cham-
ber. Whether or not media perfusion through the ureter would be
beneficial to organ culture is unknown.
Lung
For lung engineering, ventilation of media or air (mediated by
a bioreactor) has been reported (Ott et al., 2010; Petersen et al.,
2010). The transition from wet to dry ventilation is likely neces-
sary for successful re-epithelialization of the airway. Calle et al.
(2011) built a custom, user-friend, inexpensive bioreactor for lung
regeneration that utilizes negative pressure ventilation by with-
drawing air from a chamber using a syringe pump. This bioreactor
was used by Petersen et al. (2010) for regenerating rat lung tis-
sue for transplantation. Subsequent evaluation of the bioreactor
culture system for the long-term maintenance of native lung tis-
sue indicated that this bioreactor could provide sufficient nutrient
supply and mechanical stretch to foster cell survival (Petersen et al.,
2011). Interestingly, media delivery by ventilation was able to pro-
vide nutrients to the parenchyma and vasculature while perfusion
alone was not adequate to maintain cells in the parenchyma. For
scaling up to larger animal models, this bioreactor design was eas-
ily adjusted for use with rhesus macaque lungs (Bonvillain et al.,
2013). Conversely, commercial large-organ bioreactors have also
been employed for the culture of porcine or human lungs (Nichols
et al., 2013; Gilpin et al., 2014).
Heart
Heart tissue engineering applications employing both mechanical
stretch and electrical stimuli have shown promise in promoting an
organized beat function and conduction (Ott et al., 2008; Wang
et al., 2013). Ott et al. utilized a bioreactor based on a water-
jacketed working heart system from the company Radnoti. This
bioreactor incorporated pressure transducers and flow meters to
permit the measurement of preload and afterload, as well as inflow
and outflow, in order to deliver physiologically relevant intraven-
tricular pressures. In addition, synchronized electrical stimulation
could be delivered at 5–20 V for pacing of the heart construct.
Weymann et al. (2014) also used a commercial bioreactor sys-
tem, the BIOSTAT B-DCU II from Sartorius Stedim Biotech. The
system consisted of a control tower connected to a custom glass
culture vessel with precise temperature and pH control. Using
up to six peristaltic pumps, 5 L of media could be continuously
circulated through porcine hearts at a set flow rate and pressure.
Hulsmann et al. (2013) developed a low-cost, modular biore-
actor system for whole-heart cultivation that utilized coronary
perfusion and three-dimensional mechanical stimulation. Using
an operating platform based on LabVIEW®, the left ventricle of
decellularized rat hearts undergoes controlled stretching using an
inflatable latex balloon. Balloon filling was activated by a syringe
pump while a membrane pump was used to deliver volume-strokes
at set frequencies. In addition, the pressure inside the system was
monitored and controlled by a pressure sensor. For perfusion, a
pressure transducer and a peristaltic pump drove a tubing system
with an incorporated bubble trap. This highly integrated system
was augmented with a media reservoir consisting of a double-
jacket stirrer vessel with a disk-type stirrer. The reservoir was fitted
with a sparging ring for gassing media as well as a pH sensor, a
pO2 sensor, and a temperature sensor for monitoring media con-
ditions. A custom gas mixing apparatus with a flow controller
allowed fully automated conditioning of media with air/O2, CO2,
and N2 in response to pH and pO2 values. Hülsmann et al. also
noted that electrophysiological monitoring and stimulation could
easily be integrated into their bioreactor system in the future.
OPTIMIZATION OF BIOREACTOR CULTURE
Proper bioreactor culture will require optimization. Some of the
parameters that should be considered when developing a culture
protocol include volume, pressure, flow rate, culture time, and
mechanical stimuli. As scaffolds become more and more cellu-
larized, the porosity will decrease and the pressure will increase
(Lawrence et al., 2009). Therefore,monitoring pressure and adjust-
ing flow rate throughout culture will be critical to preventing
shear stress or mechanical damage to seeded cells. Additionally,
the cell types commonly used for recellularization are adhesion-
dependent; thus, anoikis may occur if cells recirculate for extended
periods of time without attaching to the matrix. Culture time and
media turnover will require investigation. Indeed, Caralt et al.
(2015) measured glucose and lactate in the media of their biore-
actor via a valve for media sampling; based on the concentrations
of glucose and lactate, they determined that oxygen was lim-
ited within their regenerating kidney. Measurement of oxygen
and nutrient turnover may be correlated to cell metabolism and,
in turn, cell number. More importantly, monitoring metabolism
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can provide information regarding potentially hypoxic conditions
if perfusion is inadequate. These types of analyses will prove
advantageous to assessing the progress of bioreactor culture.
Developing non-invasive, non-destructive technologies for
assessing organ recellularization is needed. Imaging techniques,
such as surface scanning, have been incorporated into bioreac-
tor systems and may be able to monitor organ size and structure
(Hulsmann et al., 2013). Another non-invasive/non-destructive
imaging method is the combination of multiphoton microscopy
and image correlation spectroscopy to assess mechanical proper-
ties during decellularization (Merna et al., 2013). Perhaps, a similar
system could be used to monitor organogenesis within a bioreac-
tor. Ultimately, the field of organ engineering would greatly benefit
from additional non-invasive techniques for the assessment of the
completeness of organ regeneration.
Although organ-specific chemical, electrical, and mechanical
stimuli are important to effective recellularization, these biophysi-
cal cues will need to be highly regulated. In addition, the abnormal,
or perhaps unintentional, mechanical stimuli cells undergo dur-
ing seeding and culture within the context of a bioreactor are still
enigmatic. Where some tissue engineers employ direct inocula-
tion of cells using a syringe or a needle, others utilize automated
procedures using perfusion pumps or syringe pumps. To that end,
investigators should assess the effect of laminar flow, pressure,
and shear stress during seeding and whole organ culture on cell
outcomes.
CLINICAL AND COMMERCIAL CONSIDERATIONS
The field of organ engineering is rapidly progressing toward
commercialization and clinical application. “Scaling up” decellu-
larization/recellularization to a clinically relevant size has been
demonstrated using porcine and human tissue (Sullivan et al.,
2012; Nichols et al., 2013; Yagi et al., 2013; Gilpin et al., 2014;
Weymann et al., 2014). Therefore, immunogenicity and biocom-
patibility of organ scaffolds has become a topic of interest.
WHOLE ORGAN ENGINEERING: IMMUNOGENICITY
One of the major drawbacks of traditional organ transplantation is
the requirement for life-long immunosuppression. Decellulariza-
tion provides the opportunity to reduce or eliminate donor DNA
and major histocompatibility complex (MHC) antigens. As crite-
ria for successful decellularization, removal of cells and reduction
of DNA has been widely demonstrated using different organs,
models, and methods. Decellularization of rat lungs was shown
to significantly reduce the presence of MHC class I and II mol-
ecules and DNA (Petersen et al., 2010). Scaling up to the rhesus
macaque primate model, SDS-based decellularization of kidney or
lung slices removed MHC class I and class II antigens [also known
as human leukocyte antigens (HLA) E and DR] (Nakayama et al.,
2013).
To evaluate immunogenicity, implantation of decellularized
organ scaffolds has been reported. A segment of decellularized
mouse pancreas containing <50 ng/mg dry weight DNA was
implanted subcutaneously into mice for 2 weeks; despite mononu-
clear cell infiltration, the implant did not elicit a foreign-body
response or cytotoxicity (Goh et al., 2013). In another report,
porcine kidney scaffolds seeded with murine endothelial cells
indicated no cytotoxic effect (Orlando et al., 2012); however,
orthotopic implantation of the scaffolds into pigs for 2 weeks
displayed thrombi formation (due to the presence of a denuded
vasculature) as well as infiltration of inflammatory cells (Orlando
et al., 2012). In one case, the implant was completely encased
in a fibrous capsule indicating a foreign-body response. Thus,
more work is necessary to assess immunogenicity of decellular-
ized organ scaffolds, particularly considering the diverse array of
decellularization methods in the literature.
BIOCOMPATIBILITY OF PORCINE SCAFFOLDS
Decellularization followed by recellularization using patient-
derived cells has the potential to generate a new, patient-specific
organ and eliminate the need for immunosuppression. However,
in order to increase the pool of organs available for transplantation,
scaffold sources cannot be derived from healthy, transplantable
organs. One approach is to use animal organs as a scaffold source
for human tissue engineering. Ethical issues preclude the use of
primate organs for human tissue engineering, so most researchers
have turned to pigs. When considering commercial production
and clinical use of animal organ scaffolds, pigs are an ideal choice
because they are physiologically similar to humans, breed well in
captivity, have a relatively short gestation period, and can be raised
in sterile conditions.
Decellularization of pig organs is an active area of research with
promise as well as challenges (Eitan et al., 2010; Wainwright et al.,
2010; Barakat et al., 2012; Orlando et al., 2012; Remlinger et al.,
2012; Sullivan et al., 2012; Mirmalek-Sani et al., 2013a; Nichols
et al., 2013; O’Neill et al., 2013; Park et al., 2013; Yagi et al., 2013;
Gilpin et al., 2014; Weymann et al., 2014). The main challenge is the
removal of xenoantigens – such as cell-surface galactose-alpha-l,3-
galactose – which have thus far prevented successful pig-to-human
transplantation (xenotransplantation). Although alpha-galactosyl
epitopes are widely expressed on the surface of most mammalian
cells, humans and apes lack these epitopes due to an inactivat-
ing mutation in the alpha-galactosyltransferase gene (Galili et al.,
1984, 1985). Humans have natural antibodies against alpha-gal
carbohydrates that account for ~1% of circulating immunoglobu-
lins (Galili et al., 1988). Galactose-alpha-l,3-galactose expressed on
the surface of pig endothelial cells is rapidly bound by these natural
human antibodies (Cooper et al., 1994; Sandrin and McKenzie,
1994). The antigen–antibody complex activates complement (via
the classical pathway) leading to vascular compromise and hyper-
acute rejection (Dalmasso et al., 1992). Thus, it is critical that the
alpha-gal antigen be completely removed from pig organs in order
to render the matrix immunologically inert.
Another issue with using pig organs as a scaffold source is the
risk of transmission of porcine viruses such as PERV (porcine
endogenous retrovirus), hepatitis E virus, porcine lymphotropic
herpesviruses, porcine circoviruses, or porcine cytomegalovirus
(Yoo and Giulivi, 2000; Scobie and Takeuchi, 2009). Various genet-
ically modified pigs have been developed to reduce immunogenic-
ity, but their organs can still be immunogenic (Le Bas-Bernardet
et al., 2011; Scalea et al., 2012).
Because decellularization lyses cells and removes cell debris, it
was hypothesized that this would eliminate xenoantigens as well as
porcine viruses from pig organs. However, inadequate removal of
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xenoantigens has the potential to elicit an immune response upon
implantation (Simon et al., 2003; Kasimir et al., 2006; Bastian et al.,
2008; Cicha et al., 2011; Keane et al., 2012). In addition, there are
conflicting reports about the transmission of PERV from porcine
matrices (Kallenbach et al., 2004; Prabha and Verghese, 2008).
Many groups have demonstrated that porcine organs can be
decellularized but have not assessed the removal of xenoanti-
gens or porcine viruses. Nevertheless, recent reports have shown
promise. Decellularization of sections of porcine livers with 0.1%
SDS was reported to eliminate galactose-alpha-l,3-galactose as well
as swine leukocyte antigens and PERV DNA (Park et al., 2013).
Decellularized liver segments implanted subcutaneously into pigs
had only mild immune cell infiltration in comparison to native
implants, although all implants were completely degraded after
10 weeks in vivo. Another report utilizing decellularized porcine
liver evaluated cytotoxicity in vitro using HepG2 (human hepato-
blastoma) cells (Mirmalek-Sani et al., 2013b). The cells formed a
dense layer on the edges of the scaffold with no signs of cytotoxic-
ity. Mirmalek-Sani et al. went on to evaluate immunogenicity and
biocompatibility by implanting acellular rat or pig liver scaffolds
subcutaneously into rats and saw no evidence of an inflammatory
response regardless of the scaffold source (allogenic or xenogenic).
Systemic leukocyte counts were not statistically different between
groups and no CD3+ T-cell activation was observed.
It is important that criteria for the evaluation of efficient
removal of xenoantigens and porcine viruses be established and
reported. Repeatable derivation of immunogen-reduced, biocom-
patible matrices from porcine organs will be critical to moving the
field forward.
CLINICAL APPLICATION
The clinical application of decellularized (and recellularized)
organ scaffolds is currently unknown territory. However, decel-
lularized heart valves, blood vessels, and ECM from skin, bladder,
pericardium, and small intestine submucosa has been evaluated
for clinical application (Cebotari et al., 2011; Crapo et al., 2011;
Dohmen, 2012; Moroni and Mirabella, 2014; Neumann et al.,
2014). Decellularized skin ECM scaffolds may be one of the most
predominately used acellular ECM matrices in clinical applica-
tions. There are numerous commercially available human acellular
dermal grafts, for example: AlloDerm, LifeCell; FlexHD, Ethicon;
Allopatch HD, Conmed; etc. [see Table 1 for a more complete
list of commercially available acellular dermal matrix (ADMs)].
These types of acellular matrices are not only for the regeneration
of skin but are also currently be used in surgical procedures such
as abdominal wall reconstruction, treatment of complex trauma
wounds, reconstruction of breast and areola tissue after mastec-
tomies, and treatment of chronic scalp wounds (Craft and May,
2011; Janis et al., 2012; Seaman et al., 2012; Shitrit et al., 2014).
Similar to ADMs, other decellularized ECM sheets have been
successfully used in clinical application, such as porcine urinary
bladder, which has been reported to help regenerate skeletal muscle
in patients with volumetric muscle loss (Sicari et al., 2014).
In regards to the use of commercially available decellularized
matrices in a clinical setting in the United States, recellulariza-
tion of ADM is often limited to cell migration from host tissues
after implantation because most of these clinically used dermal
Table 1 | Commercially available acellular dermal matrices.
Commerical name Manufacturer Origin
AlloDerm LifeCell Human
FlexHD Ethicon Human
Allopatch HD Conmed Human
BellaDerm Muscloskeletal Transplantation Foundation Human
DermaMatrix Synthes Human
PerioDerm Muscloskeletal Transplantation Foundation Human
AlloMax Davol Human
DermACELL LifeNet Health Human
Glyaderm Euro Skin Bank Human
matrices are available to the market due to a filing of “Pre-market
Notifications” to the Food and Drug Administration (FDA) and
are sold as medical devices. Hence, ADMs undergo a different FDA
regulatory process than tissue and cell therapies (and eventually
commercially available whole organ recellularized scaffolds, which
will be regulated as a combination product). However, these widely
used decellularized sheets may help pave the way for whole organ
recellularized scaffolds by familiarizing patients and physicians
with the concept of a decellularized matrix product. Additionally,
ADM clinical use elucidates the human body’s ability to utilize
and integrate natural, collagen-rich biological scaffolds for specific
functions such as angiogenesis.
Ultimately, the feasibility of engineered whole organs relies on
successfully navigating the regulatory requirements of the FDA,
both in the pre-market and post-market environment (Figure 2).
Under the Code of Federal Regulations, regenerative medicine
technologies fall into the category of combination product. The
definition of a combination product is as follows: “A product
comprises two or more regulated components, i.e., drug/device,
biologic/device, drug/biologic, or drug/device/biologic, that are
physically, chemically, or otherwise combined or mixed and pro-
duced as a single entity.” Combination products are regulated
through two or more branches of the FDA, but are assigned to
one office over another based on the primary means of action
of said product. Ultimately, this designation will outline the path
complex whole organs, such as lung or heart, will take toward
market approval. According to the primary means of action of
whole organs, the classification can fall either as a “biologic” or as
a “medical device” and arguments can be made for either.
CONCLUDING REMARKS
The critical components to successful recellularization are the
utilization of (1) clinically relevant, renewable cell sources, (2)
multiple seeding approaches, and (3) bioreactors with physiologi-
cally relevant organ culture conditions. Complete recellularization
is a complex task, particularly for human-sized organs. A large
number of cells encompassing a variety of cell types (parenchymal,
vascular, and support) are required for sufficient recellularization.
The ultimate goal is to use autologous cell sources to facilitate the
production of patient-specific organs to improve the outcomes of
transplantation. With these considerations in mind, the ideal cell
type will be either stem or progenitor cells. Stem cells are efficiently
expanded in culture, differentiate along multiple cell lineages, and
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FIGURE 2 | Potential FDA regulatory routes of decellularized
matrices. For classification as a device, there are classes of device
safety standards ranging from Class I (e.g., toothbrush) to Class III (e.g.,
pacemaker). However, an engineered organ will likely be classified as a
combination product. Determination of product as Pre-market
Notification or Pre-market Approval will allow for one of two routes: (1)
90 days notification to the FDA for market (for devices for similar use as
products pre-dating May 28th, 1976), or (2) clinical trials and approval
process; respectively. Both routes, once marketed and commercially
available, will undergo stringent post-market monitoring.
isolated from autologous sources. Because of the ethical issues sur-
rounding the use of ESCs, iPSCs or adult stem cells, such as ASCs or
BMSCs may be viable options. These cell types have demonstrated
potential for recellularization of the parenchyma and vasculature
of organs. Although seeding methods will vary for each organ, the
most promising results have been achieved when utilizing multi-
ple seeding routes, several cell infusions, and a variety of cell types.
Whole organ bioreactor culture must provide sufficient nutrient
delivery to the developing organ along with other physiologically
relevant stimuli, which is supported by reports of regenerated
organs displaying functionality in vivo. Moving forward, optimiz-
ing revascularization is critical to successful organ regeneration
and should be emphasized in future investigations. Lastly, the field
has just begun to scale up decellularization, recellularization, and
bioreactor technology to large animal models and human tissue.
Concurrently, evaluation of immunogenicity and biocompatibility
are of utmost importance to eventual FDA approval, commercial
viability, and clinical application.
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